Olanzapine medicine absorbed through oral mucosa

An oral mucosa and olanzapine technology, which is applied in the field of olanzapine drugs, can solve the problems of difficulty in quickly controlling the symptoms of schizophrenia in the acute phase, patients with mental illness not cooperating with treatment, and difficulty in guaranteeing treatment effects, so as to avoid the first pass of the liver. effect, improved bioavailability, fast-acting effect

Inactive Publication Date: 2012-05-16
重庆市力扬医药开发有限公司
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the olanzapine preparations used clinically are mainly tablets. Olanzapine is absorbed through the gastrointestinal tract, and it takes a certain time to take effect, so it is difficult to quickly control the symptoms of schizophrenia in the acute phase; and mental patients often do not cooperate with the treatment, and the medication compliance is poor , the drug is often placed under the tongue when taking the medicine, and spit out after the medical staff leave, it is difficult to guarantee the therapeutic effect; at the same time, because 40% of the oral dose of olanzapine has a hepatic first-pass effect, it affects the clinical use of the drug to a certain extent. The use and efficacy of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Olanzapine medicine absorbed through oral mucosa

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 (sublingual tablet)

[0024] composition:

[0025] Olanzapine 2.5g

[0026] Microcrystalline Cellulose 30g

[0027] Mannitol 25g

[0028] Sodium carboxymethyl starch 3g

[0029] Magnesium stearate 0.5g

[0030]

[0031] Made into 1000 pieces

[0032] Preparation method: Olanzapine is micronized with a jet mill to a particle size of D 90 ≤50μm, weighed according to the prescription, mixed evenly with the prescription amount of auxiliary ingredients such as microcrystalline cellulose and mannitol, directly compressed into tablets, and the hardness is controlled at 3-5kg, that is to say.

Embodiment 2

[0033] Embodiment 2 (sublingual tablet)

[0034] composition:

[0035] Olanzapine 5g

[0036] Starch 20g

[0037] Microcrystalline Cellulose 30g

[0038] 10g pregelatinized starch

[0039] Crospovidone 4g (half inside and outside)

[0040] Talc powder 0.5g

[0041]

[0042] Made into 1000 pieces

[0043] Preparation method: Olanzapine is micronized with a jet mill to a particle size of D 90 ≤30μm, mix the prescribed amount of olanzapine with auxiliary ingredients such as starch and microcrystalline cellulose, granulate with pure water as wetting agent, dry, granulate, add crospovidone and talc powder, mix Evenly, press into tablets, the hardness is controlled at 3-5kg, that is to say.

Embodiment 3

[0044] Embodiment 3 (sublingual tablet)

[0045] composition:

[0046] Olanzapine 3.5g

[0047] Lactose 30g

[0048] 40g pregelatinized starch

[0049] Croscarmellose Sodium 6g

[0050] Stevioside 5g

[0051] Peppermint Oil 0.1g

[0052] Talc powder 1.5g

[0053]

[0054]Made into 1000 pieces

[0055] Preparation method: use a ball mill to pulverize olanzapine to a particle size of D 90 ≤80μm, after uniformly mixing olanzapine, lactose, pregelatinized starch and other auxiliary ingredients, directly compressing tablets, the hardness is controlled at 2-4kg, that is.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to an olanzapine medicine absorbed through an oral mucosa. The medicine is composed of olanzapine taken as an effective medicinal component and auxiliary components acceptable in oral mucosa medicines, wherein, the auxiliary components comprise a disintegrant, a filling agent, a flavoring agent, an adhesive, a mucosa absorption enhancer, and a lubricant. Specifically, the medicine includes the following preparation forms employed currently: sublingual tablets, toroches, buccal tablets, buccal adhesive tablets, and buccal patches, etc. Able to be completely or mainly absorbed by a sublingual mucosa and / or a buccal mucosa, the medicine of the invention has the advantages of no irritation on the oral cavity, ability to substantially improve medicinal bioavailability and treatment effect, as well as convenient administration, and can bring patients good compliance.

Description

technical field [0001] The present invention relates to a medicine absorbed through oral mucosa, specifically a kind of olanzapine medicine which can be absorbed through oral mucosa, including sublingual tablet, buccal tablet, buccal tablet, oral adhesive tablet and oral patch etc. Pharmaceutical preparations absorbed wholly or mainly by oral mucosa such as sublingual mucosa and / or buccal mucosa. Background technique [0002] Olanzapine is suitable for the acute and maintenance treatment of schizophrenia and other psychosis with severe positive and / or negative symptoms, and can also relieve the secondary affective symptoms of schizophrenia and related diseases. The recommended starting dose of this product is 10mg per day, which can be taken before or after meals. Dosage ranges from 5 to 20 mg per day. The daily dose should be determined according to the clinical situation. Doses in excess of 10 mg daily should be preceded by appropriate clinical evaluation. [0003] Ola...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/5513A61P25/18
Inventor 黄华王显著刘星陈晓华吉杰标
Owner 重庆市力扬医药开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap